MCID: GLL018
MIFTS: 59

Gallbladder Cancer

Categories: Rare diseases, Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Gallbladder Cancer

MalaCards integrated aliases for Gallbladder Cancer:

Name: Gallbladder Cancer 12 50 52 41 14
Gallbladder Carcinoma 12 52 14 69
Malignant Neoplasm of Gallbladder 12 69
Gallbladder Neoplasm 12 69
Malignant Neoplasm of Gallbladder Localized 69
Localized Malignant Gallbladder Neoplasm 12
Malignant Tumor of the Gallbladder 12
Malignant Tumour of Gallbladder 12
Cancer of the Gallbladder 12
Tumor of the Gallbladder 12
Carcinoma of Gallbladder 12
Carcinoma Gallbladder 12
Gallbladder Neoplasms 42
Gallbladder Ca 12

Classifications:



Summaries for Gallbladder Cancer

MedlinePlus : 41 your gallbladder is a pear-shaped organ under your liver. it stores bile, a fluid made by your liver to digest fat. as your stomach and intestines digest food, your gallbladder releases bile through a tube called the common bile duct. the duct connects your gallbladder and liver to your small intestine. cancer of the gallbladder is rare. it is more common in women and native americans. symptoms include jaundice (yellowing of the skin and whites of the eyes) pain above the stomach fever nausea and vomiting bloating lumps in the abdomen it is hard to diagnose gallbladder cancer in its early stages. sometimes doctors find it when they remove the gallbladder for another reason. but people with gallstones rarely have gallbladder cancer. because it is often found late, it can be hard to treat gallbladder cancer. treatment options include surgery, chemotherapy, radiation, or a combination. nih: national cancer institute

MalaCards based summary : Gallbladder Cancer, also known as gallbladder carcinoma, is related to lung cancer and adenosquamous gallbladder carcinoma, and has symptoms including abdominal pain, constipation and diarrhea. An important gene associated with Gallbladder Cancer is MLH1 (MutL Homolog 1), and among its related pathways/superpathways are ERK Signaling and Development HGF signaling pathway. The drugs Oxaliplatin and Liver Extracts have been mentioned in the context of this disorder. Affiliated tissues include liver, lymph node and lung, and related phenotypes are endocrine/exocrine gland and homeostasis/metabolism

Disease Ontology : 12 A biliary tract cancer that is located in the gallbladder.

Wikipedia : 72 Gallbladder cancer is a relatively uncommon cancer. It has peculiar geographical distribution being... more...

Related Diseases for Gallbladder Cancer

Diseases related to Gallbladder Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 258)
id Related Disease Score Top Affiliating Genes
1 lung cancer 26.5 CCND1 CDH1 CDKN2A CEACAM5 EGFR ERBB2
2 adenosquamous gallbladder carcinoma 12.1
3 squamous cell carcinoma of gallbladder and extrahepatic biliary tract 11.9
4 gallbladder small cell carcinoma 11.1
5 cervical adenoid cystic carcinoma 10.9 CDKN2A TP53
6 deep angioma 10.9 CEACAM5 TP53
7 malignant skin fibrous histiocytoma 10.9 CEACAM5 KRAS
8 lung squamous cell carcinoma 10.9 CEACAM5 MUC1
9 cholangiocarcinoma, susceptibility to 10.9
10 gallbladder adenocarcinoma 10.9
11 adenocarcinoma in situ 10.8 CDKN2A KRAS TP53
12 pediatric infratentorial ependymoma 10.8 EGFR TP53
13 bile duct mucoepidermoid carcinoma 10.8 CEACAM5 MUC1
14 renal pelvis urothelial papilloma 10.8 CDH1 TP53
15 infiltrating ureter transitional cell carcinoma 10.8 EGFR ERBB2
16 mixed oligodendroglioma-astrocytoma 10.8 CEACAM5 TP53
17 gallbladder squamous cell carcinoma 10.8
18 ureter squamous cell carcinoma 10.8 CEACAM5 ERBB2
19 bladder tuberculosis 10.8 CDH1 ERBB2
20 extramedullary plasmacytoma 10.8 CEACAM5 KRAS TP53
21 orbital lymphoma 10.8 CDKN2A ERBB2 TP53
22 bile duct carcinoma 10.8
23 testis seminoma 10.8 CDKN2A ERBB2
24 spastic ataxia 3 10.8 CDKN2A MUC1 TP53
25 lipid-cell variant infiltrating bladder urothelial carcinoma 10.8 CEACAM5 TP53
26 familial episodic pain syndrome 10.8 CDH1 MLH1 TP53
27 congenital mesoblastic nephroma 10.8 EGFR KRAS TP53
28 multiple carboxylase deficiency 10.8 CDKN2A EGFR TP53
29 vulva squamous cell carcinoma 10.8 CDKN2A CEACAM5 ERBB2
30 gastric papillary adenocarcinoma 10.8 CEACAM5 KRAS MUC1
31 myotonia congenita 10.7 CDKN2A CEACAM5 ERBB2
32 tendon sheath lipoma 10.7 PTGS2 TP53
33 middle ear squamous cell carcinoma 10.7 CDKN2A EGFR TP53
34 tracheal disease 10.7 CDH1 CDKN2A TP53
35 esophagus squamous cell carcinoma 10.7 CDKN2A PTGS2 TP53
36 myeloid/lymphoid neoplasm associated with pdgfra rearrangement 10.7 CDKN2A EGFR MUC1
37 secondary hyperparathyroidism of renal origin 10.7 CDKN2A EGFR TP53
38 heavy chain disease 10.7 CDKN2A CEACAM5 TP53
39 secondary syphilis 10.7 CDH1 CEACAM5 MUC1
40 myxedema 10.7 CDKN2A EGFR TP53
41 wolffian duct adenoma 10.7 CEACAM5 KRAS MLH1
42 urethral obstruction sequence 10.7 AFP CEACAM5
43 congenital disorder of glycosylation, type if 10.7 ERBB2 TP53
44 breast sarcoma 10.7 CDH1 ERBB2 MUC1
45 breast fibrosarcoma 10.7 EGFR ERBB2 TP53
46 tumor of exocrine pancreas 10.7 CDKN2A EGFR MUC1
47 skin sarcoma 10.7 CEACAM5 EGFR ERBB2
48 fasciolopsiasis 10.7 CDKN2A PTGS2 TP53
49 larynx carcinoma in situ 10.7 CDKN2A FHIT TP53
50 occupational dermatitis 10.7 EGFR ERBB2 KRAS

Comorbidity relations with Gallbladder Cancer via Phenotypic Disease Network (PDN):


Cholangitis Cholestasis
Deficiency Anemia

Graphical network of the top 20 diseases related to Gallbladder Cancer:



Diseases related to Gallbladder Cancer

Symptoms & Phenotypes for Gallbladder Cancer

UMLS symptoms related to Gallbladder Cancer:


abdominal pain, constipation, diarrhea, dyspepsia, heartburn, icterus, nausea and vomiting, gastrointestinal gas

MGI Mouse Phenotypes related to Gallbladder Cancer:

44 (show all 14)
id Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.37 ABCB4 AFP CCND1 CDH1 CDKN2A EGFR
2 homeostasis/metabolism MP:0005376 10.36 ABCB4 AFP CCND1 CDH1 CDKN2A EGFR
3 cellular MP:0005384 10.3 ABCB4 CCND1 CDH1 CDKN2A EGFR ERBB2
4 digestive/alimentary MP:0005381 10.29 ERBB2 FHIT KRAS MLH1 MUC2 PTGS2
5 hematopoietic system MP:0005397 10.29 ABCB4 CCND1 CDKN2A EGFR FHIT KRAS
6 cardiovascular system MP:0005385 10.28 ABCB4 CCND1 CDH1 CDKN2A EGFR ERBB2
7 immune system MP:0005387 10.28 PTGS2 TIMP2 TP53 ZFX ABCB4 CCND1
8 mortality/aging MP:0010768 10.2 NMT1 PTGS2 TP53 ZFX AFP CCND1
9 neoplasm MP:0002006 10.13 ERBB2 FHIT KRAS MGMT MLH1 MUC2
10 integument MP:0010771 10.1 TP53 CCND1 CDH1 CDKN2A EGFR ERBB2
11 liver/biliary system MP:0005370 9.91 PTGS2 TP53 ABCB4 AFP CDKN2A EGFR
12 normal MP:0002873 9.81 PSCA PTGS2 TIMP2 TP53 CCND1 CDH1
13 reproductive system MP:0005389 9.73 ABCB4 AFP CCND1 CDH1 CDKN2A EGFR
14 respiratory system MP:0005388 9.28 CCND1 CDKN2A EGFR ERBB2 KRAS MGMT

Drugs & Therapeutics for Gallbladder Cancer

Drugs for Gallbladder Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 196)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxaliplatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 61825-94-3 5310940 9887054 43805 6857599
2 Liver Extracts Phase 4,Phase 2,Phase 3,Phase 1
3 Cola Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1
4
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
5
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1 154361-50-9 60953
6
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
7
Epirubicin Approved Phase 3,Phase 1 56420-45-2 41867
8
Somatostatin Approved Phase 3 38916-34-6, 51110-01-1 53481605
9
Trioxsalen Approved Phase 3,Phase 2 3902-71-4 5585
10
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
11
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
12
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
13
Ondansetron Approved Phase 3 99614-02-5 4595
14
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
15
Morphine Approved, Investigational Phase 3 57-27-2 5288826
16
Levoleucovorin Approved Phase 3,Phase 2,Phase 1 68538-85-2
17
Citalopram Approved Phase 3 59729-33-8 2771
18
leucovorin Approved, Nutraceutical Phase 3,Phase 1,Phase 2 58-05-9 143 6006
19
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 1,Phase 2 59-30-3 6037
20 Pancreatic Polypeptide Investigational Phase 3,Phase 2,Phase 1 59763-91-6
21 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
22 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
23 Antimetabolites Phase 3,Phase 2,Phase 1
24 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
25 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
26 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
27 Hormone Antagonists Phase 3
28 Hormones Phase 3
29 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3
30 Dermatologic Agents Phase 3,Phase 2,Phase 1
31 Dihematoporphyrin Ether Phase 3,Phase 2
32 Ether Phase 3,Phase 2
33 Photosensitizing Agents Phase 3,Phase 2,Phase 1
34 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Early Phase 1
35 Antiviral Agents Phase 3,Phase 2,Phase 1,Early Phase 1
36 Adjuvants, Anesthesia Phase 3
37 Analgesics Phase 3,Phase 1
38 Analgesics, Opioid Phase 3
39 Anesthetics Phase 3
40 Anesthetics, General Phase 3
41 Anesthetics, Intravenous Phase 3
42 Central Nervous System Depressants Phase 3
43 Narcotics Phase 3
44 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
45 Anti-Anxiety Agents Phase 3
46 Antiemetics Phase 3,Phase 2
47 Anti-Inflammatory Agents Phase 3
48 Antineoplastic Agents, Hormonal Phase 3
49 Antipruritics Phase 3
50 Antipsychotic Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 176)

id Name Status NCT ID Phase Drugs
1 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
2 Biliary Metal Stent Study: Metal Stents for Management of Distal Malignant Biliary Obstruction Completed NCT00280709 Phase 4
3 Palliative Biliary Stenting on the Quality of Life of Patients With Unresectable Carcinoma Gallbladder With Hiliar Block. Completed NCT00391183 Phase 2, Phase 3
4 New Chemotherapy Regimen in the Treatment of Advanced Gallbladder Carcinoma Completed NCT01053390 Phase 3 Somatostatin;epirubicin, cisplatin, LV(Leucovorin)、 5-FU(5-Fluorouracil)
5 Biliary Stenting With or Without Photodynamic Therapy in Treating Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors That Cannot Be Removed by Surgery Completed NCT00513539 Phase 3 porfimer sodium
6 Gemcitabine With or Without Cisplatin in Treating Patients With Unresectable Locally Advanced or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors Completed NCT00262769 Phase 3 cisplatin;gemcitabine hydrochloride
7 Fluorouracil, Cisplatin, and Radiation Therapy or Gemcitabine and Oxaliplatin in Treating Patients With Nonmetastatic Biliary Tract Cancer That Cannot Be Removed By Surgery Completed NCT00304135 Phase 2, Phase 3 cisplatin;gemcitabine hydrochloride;oxaliplatin
8 Capecitabine or Observation After Surgery in Treating Patients With Biliary Tract Cancer Completed NCT00363584 Phase 3 capecitabine
9 Gemcitabine Hydrochloride and Oxaliplatin or Observation in Treating Patients With Biliary Tract Cancer That Has Been Removed by Surgery Completed NCT01313377 Phase 3 gemcitabine hydrochloride;oxaliplatin
10 Comprehensive Electronic Cancer Support System for the Treatment of Cancer Related Symptoms Completed NCT01640522 Phase 3
11 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
12 Ondansetron With or Without Dexamethasone to Prevent Vomiting in Patients Receiving Radiation Therapy to the Upper Abdomen Completed NCT00016380 Phase 3 dexamethasone;ondansetron
13 E-MOSAIC Electronic Tool to Monitor Symptoms Completed NCT00477919 Phase 3
14 Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer Recruiting NCT02170090 Phase 3 Gemcitabine;Cisplatin;Capecitabine
15 Clinical Trial of Adjuvant Chemotherapy Followed by Concurrent Chemoradiotherapy Compared With Adjuvant Chemotherapy Alone in Patients With Gallbladder Carcinoma and Extrahepatic Cholangiocarcinoma Recruiting NCT02798510 Phase 3 capecitabine;gemcitabine
16 Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers Recruiting NCT01926236 Phase 3 L-folinic acid;5 FU;Oxaliplatin
17 Perioperative Therapy Preoperative Chemotherapy Versus Chemoradiotherapy in Locally Advanced Gall Bladder Cancers Not yet recruiting NCT02867865 Phase 2, Phase 3 Gemcitabine;Cisplatin
18 Gemcitabine With or Without Capecitabine in Treating Patients With Locally Advanced, Unresectable, or Metastatic Biliary Cancer Terminated NCT00658593 Phase 3 capecitabine;gemcitabine hydrochloride
19 Escitalopram in Treating Depression in Patients With Advanced Lung or Gastrointestinal Cancer Terminated NCT00387348 Phase 3 escitalopram oxalate;Placebo
20 XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary Tumors Terminated NCT00090025 Phase 3 becatecarin;5-Fluorouracil Plus Leucovorin
21 Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo Terminated NCT00332280 Phase 2, Phase 3 AMT2003
22 Stent Placement With or Without Photodynamic Therapy Using Porfimer Sodium as Palliative Treatment in Treating Patients With Stage III or Stage IV Cholangiocarcinoma That Cannot Be Removed By Surgery Withdrawn NCT00253617 Phase 3 porfimer sodium
23 Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Patients With Biliary Tract and Gallbladder Cancer Unknown status NCT00142480 Phase 2 Capecitabine;Oxaliplatin;Bevacizumab
24 A Randomized, Open, Prospective Clinical Research of Fluorouracil Implant to Improve Surgical Gallbladder Cancer and Bile Duct Cancer Unknown status NCT01317069 Phase 2 Fluorouracil implant
25 Liposomal Doxorubicin in Treating Patients With Liver or Bile Duct Cancer Unknown status NCT00003296 Phase 2 pegylated liposomal doxorubicin hydrochloride
26 HAI Via Interventionally Implanted Port Catheter Systems Unknown status NCT00356161 Phase 2
27 Gemcitabine, Oxaliplatin and Panitumumab in Kras/B-raf Wild-Type Biliary Track and Gallbladder Cancer Completed NCT01308840 Phase 2 Panitumumab;oxaliplatin;gemcitabine
28 Study of Gemcitabine and Carboplatin in the Treatment of Metastatic or Recurrent Cholangiocarcinoma/Gallbladder Cancer Completed NCT00660140 Phase 2 Gemcitabine;Carboplatin
29 Gemcitabine and Cisplatin for Gallbladder and Biliary Tract Cancer Completed NCT00123825 Phase 2 Gemcitabine;Cisplatin
30 Gemcitabine Plus Pemetrexed Disodium in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer Completed NCT00059865 Phase 1, Phase 2 gemcitabine hydrochloride;pemetrexed disodium
31 Combination Chemotherapy in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer Completed NCT00009893 Phase 2 fluorouracil;gemcitabine hydrochloride;leucovorin calcium
32 S0202 Gemcitabine and Capecitabine for Unresectable Locally Advanced Metastatic Gallbladder Cancer or Cholangiocarcinoma Completed NCT00033540 Phase 2 capecitabine;gemcitabine hydrochloride
33 S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or Cholangiocarcinoma Completed NCT00238212 Phase 2 sorafenib tosylate
34 Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery Completed NCT00478140 Phase 2
35 Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma Completed NCT01093222 Phase 2 Erlotinib Hydrochloride;Sorafenib Tosylate
36 Dolastatin 10 in Treating Patients With Metastatic Or Recurrent Liver, Bile Duct, or Gallbladder Cancer Completed NCT00003557 Phase 2 dolastatin 10
37 Triapine and Gemcitabine Hydrochloride in Gallbladder Cancer Completed NCT00075504 Phase 2 triapine;gemcitabine
38 Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Biliary Tract and Gallbladder Cancer Completed NCT00361231 Phase 2 Bevacizumab;Gemcitabine;Oxaliplatin
39 Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery Completed NCT02042443 Phase 2 Capecitabine;Fluorouracil;Leucovorin Calcium;Trametinib
40 Irinotecan in Treating Patients With Advanced Gallbladder or Bile Duct Cancer Completed NCT00003276 Phase 2 irinotecan hydrochloride
41 Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer Completed NCT00033462 Phase 2 erlotinib hydrochloride
42 Gemcitabine and Capecitabine in Treating Patients With Advanced and/or Inoperable Cholangiocarcinoma or Carcinoma of the Gallbladder Completed NCT00084942 Phase 2 capecitabine;gemcitabine hydrochloride
43 DX-8951f in Treating Patients With Biliary Cancer Completed NCT00005938 Phase 2 exatecan mesylate
44 Oxaliplatin and Capecitabine in Patients With Unresectable Cholangiocarcinoma Completed NCT00338988 Phase 2 Capecitabine;Oxaliplatin
45 Gemcitabine and Cisplatin Plus Sorafenib in Patients With Advanced Biliary Tract Carcinomas Naive to Systemic Therapy Completed NCT00919061 Phase 2 Gemcitabine;Cisplatin;Sorafenib
46 Efficacy of Imatinib and 5-FU/Leucovorin in Patients With Advanced Carcinoma of the Gallbladder and Bile Duct Completed NCT01153750 Phase 2 Glivec
47 Vandetanib Gemcitabine Or Placebo Plus Gemcitabine Or Vandetanib Monotherapy In Advanced Biliary Tract Cancer Completed NCT00753675 Phase 2 ZD6474, Vandetanib;ZD6474, Vandetanib;Gemcitabine;Placebo matching ZD6474
48 A Study of Combination of Gemcitabine, Oxaliplatin (GEMOX)-Sorafenib in Patients With Advanced Biliary Tract Cancer Completed NCT00955721 Phase 1, Phase 2 Gemcitabine;Oxaliplatin;Sorafenib
49 A Study of Gemcitabine, Capecitabine and Bevacizumab to Treat Cancer of the Gall Bladder or Bile Ducts Completed NCT01007552 Phase 2 Gemcitabine, Capecitabine and Bevacizumab
50 Avastin and Tarceva for Upper Gastrointestinal Cancers Completed NCT00350753 Phase 2 Erlotinib and bevacizumab

Search NIH Clinical Center for Gallbladder Cancer

Cochrane evidence based reviews: gallbladder neoplasms

Genetic Tests for Gallbladder Cancer

Anatomical Context for Gallbladder Cancer

MalaCards organs/tissues related to Gallbladder Cancer:

39
Liver, Lymph Node, Lung, Skin, Eye, Small Intestine, Testes

Publications for Gallbladder Cancer

Articles related to Gallbladder Cancer:

(show top 50) (show all 732)
id Title Authors Year
1
Predicting Resectability in Gallbladder Cancer: the Tata Memorial Hospital Staging System. ( 28812197 )
2017
2
Common genetic variation and risk of gallbladder cancer in India: a case-control genome-wide association study. ( 28274756 )
2017
3
Retracted: Long Noncoding RNA KIAA0125 Potentiates Cell Migration and Invasion in Gallbladder Cancer. ( 28929110 )
2017
4
The technique of laparoscopic hepatic bisegmentectomy with regional lymphadenectomy for gallbladder cancer. ( 28928327 )
2017
5
Arctigenin induced gallbladder cancer senescence through modulating epidermal growth factor receptor pathway. ( 28459363 )
2017
6
Predictors of incidental gallbladder cancer in patients undergoing cholecystectomy for benign gallbladder disease: Results from a population-based gallstone surgery registry. ( 28400123 )
2017
7
Impact of insurance status on the survival of gallbladder cancer patients. ( 28881677 )
2017
8
Extended Lymphadenectomy Is Required for Incidental Gallbladder Cancer Independent of Cystic Duct Lymph Node Status. ( 28752405 )
2017
9
DUSP1 inhibits cell proliferation, metastasis and invasion and angiogenesis in gallbladder cancer. ( 28129656 )
2017
10
MYBL2 is a Potential Prognostic Marker that Promotes Cell Proliferation in Gallbladder Cancer. ( 28427077 )
2017
11
Decreased expression of hsaa89miRa89372 predicts poor prognosis in patients with gallbladder cancer by affecting chloride intracellular channel 1. ( 28944858 )
2017
12
Minimally invasive and open gallbladder cancer resections: 30- vs 90-day mortality. ( 28823371 )
2017
13
Healthy dietary patterns and incidence of biliary tract and gallbladder cancer in a prospective study of women and men. ( 27870981 )
2017
14
Pathologic and Prognostic Implications of Incidental versus Nonincidental Gallbladder Cancer: A 10-Institution Study from the United States Extrahepatic Biliary Malignancy Consortium. ( 28738935 )
2017
15
Mutational frequency of KRAS, NRAS, IDH2, PIK3CA, and EGFR in North Indian gallbladder cancer patients. ( 28900470 )
2017
16
MiR-143-5p Deficiency Triggers EMT and Metastasis by Targeting HIF-1I+ in Gallbladder Cancer. ( 28803245 )
2017
17
Comparative Analysis of Mutational Profile of Sonic hedgehog Gene in Gallbladder Cancer. ( 28058596 )
2017
18
Acute cholecystitis, chronic cholecystitis or gallbladder cancer? ( 28073581 )
2017
19
Laparoscopic versus open treatment of gallbladder cancer: A systematic review and meta-analysis. ( 28782743 )
2017
20
Downregulation of BRD4 inhibits gallbladder cancer proliferation and metastasis and induces apoptosis via PI3K/AKT pathway. ( 28766687 )
2017
21
The NmrA-like family domain containing 1 pseudogene Loc344887 is amplified in gallbladder cancer and promotes epithelial-mesenchymal transition. ( 28245089 )
2017
22
The clinical significance and underlying correlation of pStat-3 and integrin I+vI^6 expression in gallbladder cancer. ( 28061445 )
2017
23
Epigenetic Downregulation of PTEN in Gallbladder Cancer. ( 28124240 )
2017
24
Incidence rate for gallbladder cancer in Japanese in Japan and in the United States from the Cancer Incidence in Five Continents. ( 28064205 )
2017
25
The emerging role of long non-coding RNA in gallbladder cancer pathogenesis. ( 27894946 )
2017
26
Prevalence of gallbladder cancer In patients submitted to cholecystectomy: experience of the University Hospital, Faculty of Medical Sciences, State University of Campinas - UNICAMP. ( 28767800 )
2017
27
Long non-coding RNA LINC00152 promotes gallbladder cancer metastasis and epithelial-mesenchymal transition by regulating HIF-1I+ via miR-138. ( 28077595 )
2017
28
Threonine and tyrosine kinase may serve as a prognostic biomarker for gallbladder cancer. ( 28883705 )
2017
29
Re: Incidental Gallbladder Cancer Visualized From Posttreatment 131I Whole-Body Scan. ( 28079570 )
2017
30
Biofilm Producing Salmonella Typhi: Chronic Colonization and Development of Gallbladder Cancer. ( 28858232 )
2017
31
WNT inhibitory factor 1 promoter hypermethylation is an early event during gallbladder cancer tumorigenesis that predicts poor survival. ( 28438695 )
2017
32
Casticin induces apoptosis and G0/G1 cell cycle arrest in gallbladder cancer cells. ( 28070171 )
2017
33
Lymph node micrometastasis in gallbladder cancer. ( 28782079 )
2017
34
INCIDENTAL GALLBLADDER CANCER - THE FIRST REPORT FROM SUB-SAHARAN AFRICA. ( 28876646 )
2017
35
To Resect or Not to Resect Extrahepatic Bile Duct in Gallbladder Cancer? ( 28090223 )
2017
36
Expression Analysis of Survivin and XIAP in Gallbladder Cancer: a Case-control Study in Indo-Gangetic Plain. ( 28952057 )
2017
37
Indication of extrahepatic bile duct resection for gallbladder cancer. ( 28875312 )
2017
38
Mortality trend of gallbladder cancer in AraucanA-a Region, Chile, 2004-2014. ( 28885998 )
2017
39
CYP1A1, GSTM1, GSTT1 and TP53 Polymorphisms and Risk of Gallbladder Cancer in Bolivians. ( 26925680 )
2016
40
Body Mass Index Can Increase the Risk of Gallbladder Cancer: A Meta-Analysis of 14 Cohort Studies. ( 27899789 )
2016
41
Annexin A4-nuclear factor-I_B feedback circuit regulates cell malignant behavior and tumor growth in gallbladder cancer. ( 27491820 )
2016
42
Indications for major hepatectomy and combined procedures for advanced gallbladder cancer. ( 27864927 )
2016
43
Current Status on Cholangiocarcinoma and Gallbladder Cancer. ( 27995089 )
2016
44
Unexpected gallbladder cancer: Surgical strategies and prognostic factors. ( 27648157 )
2016
45
Laparoscopic Management of Gallbladder Cancer: A Stepwise Approach. ( 27456958 )
2016
46
The Expression of Notch 1 and Notch 3 in Gallbladder Cancer and Their Clinicopathological Significance. ( 26634853 )
2016
47
Technical Aspects of Gallbladder Cancer Surgery. ( 27017862 )
2016
48
To improve outcomes of gallbladder cancer we need to better understand it! ( 27500397 )
2016
49
Spontaneous Hepatic Infarction in a Patient with Gallbladder Cancer. ( 27462232 )
2016
50
Gallstones and the Risk of Gallbladder Cancer Mortality: A Cohort Study. ( 27575712 )
2016

Variations for Gallbladder Cancer

ClinVar genetic disease variations for Gallbladder Cancer:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Pathogenic/Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
2 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
3 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
4 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
5 TP53 NM_000546.5(TP53): c.535C> T (p.His179Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs587780070 GRCh37 Chromosome 17, 7578395: 7578395
6 PIK3CA NM_006218.3(PIK3CA): c.1635G> T (p.Glu545Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913275 GRCh37 Chromosome 3, 178936093: 178936093
7 PIK3CA NM_006218.3(PIK3CA): c.1633G> C (p.Glu545Gln) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
8 ERBB2 NM_004448.3(ERBB2): c.2524G> A (p.Val842Ile) single nucleotide variant Pathogenic/Likely pathogenic rs1057519738 GRCh37 Chromosome 17, 37881332: 37881332
9 TP53 NM_000546.5(TP53): c.523C> G (p.Arg175Gly) single nucleotide variant Pathogenic/Likely pathogenic rs138729528 GRCh37 Chromosome 17, 7578407: 7578407

Expression for Gallbladder Cancer

Search GEO for disease gene expression data for Gallbladder Cancer.

Pathways for Gallbladder Cancer

Pathways related to Gallbladder Cancer according to GeneCards Suite gene sharing:

(show all 34)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.83 CCND1 CDH1 CDKN2A EGFR ERBB2 KRAS
2
Show member pathways
12.75 CDH1 ERBB2 KRAS PTGS2 TP53
3 12.47 CCND1 CDKN2A MGMT MLH1 TP53
4
Show member pathways
12.43 CDH1 EGFR ERBB2 KRAS MUC1 TP53
5
Show member pathways
12.41 CCND1 CDH1 CDKN2A EGFR ERBB2 FHIT
6 12.39 CCND1 CDKN2A EGFR ERBB2 KRAS PTGS2
7 12.32 CCND1 CDH1 CDKN2A TP53
8
Show member pathways
12.27 CCND1 EGFR ERBB2 PTGS2
9
Show member pathways
12.26 CCND1 EGFR ERBB2 KRAS TP53
10 12.25 CCND1 CDKN2A KRAS TP53
11 12.24 CCND1 EGFR ERBB2 KRAS TP53
12
Show member pathways
12.21 CCND1 EGFR ERBB2 KRAS TP53
13 12.21 CCND1 CDH1 CDKN2A EGFR ERBB2 KRAS
14 12.08 CCND1 CDH1 EGFR KRAS TP53
15 12.04 AFP EGFR MLH1 TP53
16
Show member pathways
12.03 CCND1 EGFR ERBB2 KRAS
17 11.97 CCND1 EGFR PTGS2 TP53
18 11.93 CCND1 MUC1 PTGS2 TP53
19 11.93 CCND1 CDKN2A KRAS MGMT MLH1 TP53
20 11.92 CCND1 CDH1 EGFR KRAS MLH1 PTGS2
21 11.89 CCND1 CDKN2A ERBB2 KRAS TP53
22 11.78 CCND1 FHIT PTGS2 TP53
23 11.78 CCND1 CDKN2A EGFR KRAS MGMT TP53
24 11.69 CDKN2A ERBB2 MLH1 TP53
25 11.68 CDH1 EGFR ERBB2
26 11.62 EGFR ERBB2 KRAS TP53
27 11.56 EGFR ERBB2 KRAS
28 11.52 CCND1 PTGS2 TP53
29 11.49 EGFR KRAS PTGS2
30 11.49 CCND1 CDKN2A EGFR TP53
31 11.39 CEACAM5 MUC1 TIMP2
32 11.25 CDH1 EGFR ERBB2
33 11.22 EGFR ERBB2 KRAS
34 11.03 CCND1 CDH1 CDKN2A EGFR ERBB2 KRAS

GO Terms for Gallbladder Cancer

Biological processes related to Gallbladder Cancer according to GeneCards Suite gene sharing:

(show all 16)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of protein phosphorylation GO:0001934 9.76 CCND1 EGFR ERBB2 KRAS
2 liver development GO:0001889 9.73 CCND1 EGFR KRAS
3 response to glucocorticoid GO:0051384 9.69 CCND1 KRAS PTGS2
4 Ras protein signal transduction GO:0007265 9.67 CDKN2A KRAS TP53
5 positive regulation of MAP kinase activity GO:0043406 9.65 EGFR ERBB2 KRAS
6 ERBB2 signaling pathway GO:0038128 9.58 EGFR ERBB2 KRAS
7 response to estradiol GO:0032355 9.56 ABCB4 CCND1 EGFR PTGS2
8 replicative senescence GO:0090399 9.55 CDKN2A TP53
9 positive regulation of cellular senescence GO:2000774 9.54 CDKN2A KRAS
10 mitotic G1 DNA damage checkpoint GO:0031571 9.52 CCND1 TP53
11 response to organic substance GO:0010033 9.46 ABCB4 CCND1 CDH1 PTGS2
12 negative regulation of immature T cell proliferation in thymus GO:0033088 9.43 CDKN2A ERBB2
13 response to drug GO:0042493 9.43 ABCB4 CCND1 CDH1 MGMT PTGS2 TIMP2
14 maintenance of permeability of blood-brain barrier GO:0035633 9.37 ABCB4 PTGS2
15 response to UV-A GO:0070141 9.32 CCND1 EGFR
16 response to organic cyclic compound GO:0014070 9.02 ABCB4 CCND1 EGFR MGMT PTGS2

Molecular functions related to Gallbladder Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 8.96 EGFR ERBB2
2 protein phosphatase binding GO:0019903 8.8 EGFR ERBB2 TP53

Sources for Gallbladder Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....